Leerink Partnrs Estimates Immunocore Q1 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Immunocore in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang anticipates that the company will earn ($0.48) per share for the quarter. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s FY2025 earnings at ($1.78) EPS.

Several other equities analysts also recently weighed in on IMCR. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Monday, January 27th. Needham & Company LLC restated a “buy” rating and set a $71.00 price target on shares of Immunocore in a research note on Thursday. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Finally, Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $72.00 to $38.00 in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Down 3.9 %

Immunocore stock opened at $29.58 on Friday. Immunocore has a 12 month low of $27.69 and a 12 month high of $72.05. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The stock has a fifty day simple moving average of $30.06 and a two-hundred day simple moving average of $31.95. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -31.14 and a beta of 0.77.

Hedge Funds Weigh In On Immunocore

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jefferies Financial Group Inc. acquired a new position in shares of Immunocore during the fourth quarter valued at approximately $4,868,000. GF Fund Management CO. LTD. purchased a new stake in shares of Immunocore in the fourth quarter valued at $25,000. Woodline Partners LP grew its stake in Immunocore by 19.4% during the 4th quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock valued at $9,678,000 after acquiring an additional 53,378 shares in the last quarter. Tang Capital Management LLC lifted its position in Immunocore by 40.7% in the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock worth $45,890,000 after buying an additional 450,000 shares in the last quarter. Finally, Tema Etfs LLC acquired a new stake in Immunocore during the fourth quarter valued at $330,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.